Cipla (CIPLA) investor relations material

Executive summary

• Achieved record FY26 revenue of INR 28,163 crore, with double-digit growth across India, North America, and Africa, and robust Q4 performance despite headwinds.

• Surpassed INR 12,500 crore in India revenue and $780 million in North America, with strong launches in respiratory, diabetes, and urology segments.

• Strategic partnerships and acquisitions, including Eli Lilly, MannKind, Pfizer, and full acquisition of Inzpera Healthscience, enhanced the portfolio.

• Audited standalone and consolidated financial results for FY26 were approved, with an unmodified audit opinion and a recommended final dividend of ₹13 per share.

• Completed acquisition and initiated amalgamation of Inzpera Healthscience Limited.

Financial highlights

• FY26 consolidated revenue: INR 28,163 crore; Q4 revenue: INR 6,541 crore.

• EBITDA margin: 15.2% for Q4, 21% for FY26; EBITDA for FY26: INR 5,925 crore.

• PAT for FY26: INR 3,879 crore (13.8% margin); Q4 PAT: INR 555 crore (8.5% margin).

• Net profit for FY26: ₹3,861.74 crore; basic EPS: ₹48.03.

• R&D investment: INR 1,974 crore for FY26 (7% of revenue).

Outlook and guidance

• Targeting double-digit growth in India and $1 billion North America run rate by end of FY27, excluding lanreotide.

• Four respiratory assets and multiple complex generics to be filed or commercialized in FY27-FY28.

• EBITDA margin guidance for FY27: 18.5%-20%, with higher margins expected in H2 as new launches ramp up.

• Continued focus on chronic therapies, respiratory, and complex generics; 70 new launches planned in India.

• Dividend payout planned within 30 days of AGM approval.